CN108892654B - 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用 - Google Patents

含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用 Download PDF

Info

Publication number
CN108892654B
CN108892654B CN201810534253.5A CN201810534253A CN108892654B CN 108892654 B CN108892654 B CN 108892654B CN 201810534253 A CN201810534253 A CN 201810534253A CN 108892654 B CN108892654 B CN 108892654B
Authority
CN
China
Prior art keywords
compound
cancer
preparation
infrared
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810534253.5A
Other languages
English (en)
Other versions
CN108892654A (zh
Inventor
田间
洪学传
陈梓杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Zhenhao Biotechnology Co ltd
Original Assignee
Wuhan Zhenhao Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Zhenhao Biotechnology Co ltd filed Critical Wuhan Zhenhao Biotechnology Co ltd
Priority to CN201810534253.5A priority Critical patent/CN108892654B/zh
Publication of CN108892654A publication Critical patent/CN108892654A/zh
Application granted granted Critical
Publication of CN108892654B publication Critical patent/CN108892654B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/145—Styryl dyes the ethylene chain carrying an heterocyclic residue, e.g. heterocycle-CH=CH-C6H5
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1003—Carbocyclic compounds
    • C09K2211/1007—Non-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1003—Carbocyclic compounds
    • C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1092—Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1096—Heterocyclic compounds characterised by ligands containing other heteroatoms

Abstract

本发明公开了一类含有4‑二氰基甲基苯并吡喃和三苯胺的近红外荧光成像剂及其制备方法。在该荧光化合物的三苯胺上引入可修饰基团，增加的可修饰位点可用于连接不同的生物活性物质，进而改善其水溶性与生物相容性，扩大其在生物医学领域的应用范围。本发明的荧光成像剂具有荧光强度高，无毒，生物相容性好等优点，具有极好的应用前景。本发明还公开了该荧光成像剂在肿瘤成像领域的应用。另外，该成像剂可修饰性好，还可用于多种疾病标志物的体外检测。

Description

含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方 法和应用
技术领域
本发明属于生物医学材料领域中的肿瘤荧光成像领域，具体涉及一类可修饰的含4-二氰基甲基苯并吡喃单元的近红外染料及其制备方法以及在生物医学荧光成像领域中的应用。
背景技术
癌症(又称恶性肿瘤)严重威胁着人类健康。由于医疗技术水平的限制，目前缺乏对晚期癌症的有效治疗手段，所以癌症的早期诊断对患者来说尤为重要，如果能早期诊断肿瘤并及时采取治疗，可以显著提高癌症患者的存活率。非侵入式的活体荧光成像等分子影像技术的出现为癌症的早期诊断开拓了新的发展道路。
生物组织在<700nm范围内有较强的自身荧光且有严重的光吸收，会严重干扰荧光成像效果。在近红外区(700～1600nm)生物组织光吸收或自身荧光强度都很小，近红外荧光成像技术受到越来越多的关注。由于近红外荧光对生物组织穿透能力较强，且成像信噪比和分辨率都较高，近红外荧光成像更有希望在未来的活体成像、肿瘤早期诊断等领域发挥重大作用。
迄今为止，近红外荧光成像材料主要为生物相容性差，毒性大或生物体难以吸收、代谢、排泄的成像试剂，主要包括单层碳纳米管(Nat.Photonics.,2014,8,723-730；Angew.Chem.Int.Ed.,2015,54,14758-14762)、高分子聚合物(Nat.Commun.,2014,5,4206)、量子点(ACS.Nano.,2012,6,3695-3702；Angew.Chem.Int.Ed.,2012,51,9818-9821；Biomaterials.,2015,53,265-273)、稀土纳米微粒(Nat.Commun.,2013,4,2199；J.Mater.Chem.B.,2016,4,87-95)等。
为了获得具有优异成药性的近红外荧光成像探针，非常需要发展具有高灵敏度、高生物相容性、高发光亮度、光稳定性好、无毒且更易于排泄的小分子近红外荧光成像染料。
发明内容
本发明公开了一类含有4-二氰基甲基苯并吡喃和三苯胺的近红外荧光成像剂及其制备方法。具体来讲，本发明涉及一类可以用于癌症诊断成像的荧光探针材料，并成功地将材料应用于肿瘤荧光成像。
为实现上述发明目的，本发明提供如下技术方案：
一类含4-二氰基甲基苯并吡喃单元的近红外染料，具有通式(1)所述的结构：
Figure BDA0001677435080000021
其中：X为：O，S或Se；
R1，R2独立地为：
Figure BDA0001677435080000022
Figure BDA0001677435080000023
R1和R2不同时为H，n＝0～18，m＝1～200，X＝F，Cl，Br，I或N3。
所述的具有通式(1)所示的结构的荧光化合物，其荧光发射波长为680～800nm。
一种制备通式(1)所述的荧光化合物的方法，反应路线如下：
Figure BDA0001677435080000031
反应过程为：
取化合物(2)和(3)加入反应容器中，在氮气或氩气保护下加入甲苯溶解，向反应液中通入氩气或氮气排除体系内氧气，加入哌啶和醋酸，然后在氮气或氩气保护下在115℃回流反应8～12小时，反应结束后纯化得到产品(1)。
本发明用于生物体内成像的近红外荧光成像探针，特别是应用于癌症诊断中，是在通式(1)所示的化合物可修饰位点修饰上聚乙二醇、多肽、蛋白、核酸适配体、叶酸及其衍生物所得。此处，癌症主要指肺癌、脑胶质瘤、乳腺癌、前列腺癌、黑色素瘤、结肠癌、胃癌、食道癌、宫颈癌和卵巢癌。本发明公开了所述的近红外荧光成像探针在生物体内成像中的应用。
本发明所得的如通式(1)所述的终产物为具有可修饰基团的全新化合物，其荧光发射波长位于近红外区，无毒，生物相容性好，易被生物体吸收和代谢。经不同后修饰或包载后，可用于肿瘤等不同疾病的检测以及血管和淋巴结成像。
本发明的近红外荧光成像探针，从实施例中可知该方案合成路线简单，反应效率高，收率高，具有较高的工业应用前景。本发明的创造性在于将4-二氰基甲基苯并吡喃中的氧原子替换为硫或硒，可增加荧光染料的发射波长，从而增加其荧光成像的穿透能力和分辨率。三苯胺上引入可修饰基团，增加的可修饰位点可用于连接不同的生物活性官能团，进而增加荧光探针的应用领域以及改善其水溶性和生物相容性。在生物医学成像实验中发现该荧光探针成像效果非常好，具有广阔的应用前景。
附图说明
图1为具体实施方式中近红外荧光成像探针1a的合成方法。
图2为近红外荧光成像探针1a在水中的吸收和荧光发射光谱图。
图3为尾静脉注射化合物1a进入右前肢接种肿瘤细胞的荷瘤小鼠体内近红外成像效果。
图4为将尾静脉注射1a进入右前肢接种肿瘤细胞的荷瘤小鼠体内，20小时后将小鼠解剖，离体组织和器官的近红外成像效果。
具体实施方式
以下结合附图对本发明的优选实施例进行说明，应当理解，此处所描述的优选实施例仅用于说明和解释本发明，并不用于限定本发明。
Figure BDA0001677435080000041
实施例1：化合物2的制备
冰浴条件下，将POCl3(7.83mL、10eq)滴入DMF(7.77mL、11eq)中，维持此温度反应2小时。冰浴条件下，取化合物1(3.5g、7.18mmol)溶于2mLDMF，滴入反应体系中，室温反应过夜。反应结束后，直接将反应也倒入冰水中，用碳酸钠将溶液pH调至近中性，然后用EA萃取，水(50mL×3)洗三次，饱和食盐水(50mL×3)洗三次。有机相用无水硫酸钠干燥，过滤，滤液旋干过硅胶柱(PE:EA＝20:1)得3.5g化合物2。收率：94％。
化合物结构测定数据如下：
1H NMR(400MHz,CDCl3)δ9.80(s,1H),7.68(d,J＝8.6Hz,2H),7.34(t,J＝7.8Hz,2H),7.19(t,J＝7.6Hz,5H),7.11(d,J＝8.3Hz,2H),7.00(d,J＝8.6Hz,2H),4.23–4.18(m,2H),2.96(t,J＝7.7Hz,2H),2.64(t,J＝7.8Hz,2H),1.03–0.98(m,2H),0.06(s,9H).
13C NMR(101MHz,CDCl3)δ190.39,172.95,153.39,146.12,144.24,137.73,131.32,129.73,129.68,128.93,126.48,126.26,125.09,119.06,62.75,35.94,30.42,17.33,-1.42.
HRMS(ESI)Calcd for:C27H32NO3Si+([M+H]+):446.6415.Found:446.6466.
实施例2：化合物4的制备
取化合物2(445mg，1mmol)、化合物3(208mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得417mg化合物4。收率：65％。
化合物4结构测定数据如下：
1H NMR(400MHz,CDCl3)δ8.91(d,J＝8.3Hz,1H),7.78–7.70(m,1H),7.62–7.54(m,2H),7.44(t,J＝8.9Hz,3H),7.34(t,J＝7.8Hz,2H),7.21–7.14(m,5H),7.07(dd,J＝26.8,8.5Hz,4H),6.81(s,1H),6.64(d,J＝15.8Hz,1H),4.30–4.16(m,2H),2.97(t,J＝7.8Hz,2H),2.65(t,J＝7.8Hz,2H),1.08–0.96(m,2H),0.07(s,9H)
13C NMR(101MHz,CDCl3)δ173.04,158.24,152.81,152.37,150.30,146.63,144.74,138.82,136.98,134.45,129.59,129.53,129.27,127.18,125.88,125.79,125.60,124.36,121.05,118.56,117.93,117.16,116.11,115.47,106.09,62.77,61.41,36.01,30.41,17.34,-1.43.
HRMS(ESI)Calcd for:C40H38N3O3Si+([M+H]+):636.8465.Found:636.8478.
实施例3：化合物5的制备
取化合物4(20mg，0.03145mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得15mg化合物5，收率89％。
化合物5结构测定数据如下：
1H NMR(400MHz,CDCl3)δ8.92(dd,J＝8.4,1.0Hz,1H),7.78–7.71(m,1H),7.61–7.54(m,2H),7.49–7.41(m,3H),7.34(t,J＝7.8Hz,2H),7.17(dd,J＝15.1,6.4Hz,5H),7.07(dd,J＝26.3,8.5Hz,4H),6.83(s,1H),6.66(d,J＝15.8Hz,1H),2.99(t,J＝7.7Hz,2H),2.74(t,J＝7.7Hz,2H).
13C NMR(101MHz,CDCl3)δ177.84,158.22,152.87,152.38,150.24,146.60,144.91,138.77,136.45,134.46,129.61,129.49,129.26,127.26,125.86,125.83,125.61,124.39,121.14,118.55,118.19,117.94,116.84,115.56,106.14,53.47,30.05,29.35.
HRMS(ESI)Calcd for:C35H26N3O3 +([M+H]+):536.6105.Found:536.6167.
Figure BDA0001677435080000061
实施例4：化合物7的制备
取化合物2(445mg，1mmol)、化合物6(224mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得405mg化合物7。收率：62％。据文献报道，类似化合物B-DCM-P的最大发射波长为660nm(Journal of Materials ChemistryB,4(27))，而我们将其中的氧原子替换为硫原子后，最大发射波长红移了70nm，达到730nm。显然，荧光探针有着更长的发射波长就有着更低的活体组织自荧光干扰、更高的成像分辨率、更深的组织穿透能力，也就有着更有潜力的应用前景。
化合物7结构测定数据如下：
1H NMR(400MHz,CDCl3)δ8.93(d,J＝8.2Hz,1H),7.66(ddd,J＝15.1,8.1,1.2Hz,2H),7.59–7.54(m,1H),7.52(s,1H),7.40(d,J＝8.7Hz,2H),7.33(t,J＝7.9Hz,2H),7.24(d,J＝16.0Hz,1H),7.20–7.12(m,5H),7.06(dd,J＝23.4,8.6Hz,4H),6.98(d,J＝16.0Hz,1H),4.25–4.17(m,2H),2.96(t,J＝7.8Hz,2H),2.65(t,J＝7.8Hz,2H),1.06–0.97(m,2H),0.07(s,9H).
13C NMR(101MHz,CDCl3)δ173.05,155.84,150.01,148.06,146.70,144.82,137.21,136.86,134.89,131.84,129.56,129.49,128.95,128.33,128.13,127.48,127.35,125.76,125.67,125.47,124.23,122.32,121.30,120.70,116.20,67.58,62.76,36.01,30.41,17.34,-1.44.
HRMS(ESI)Calcd for:C40H38N3O2SSi+([M+H]+):652.9075.Found:652.9087.
实施例5：化合物8的制备
取化合物7(20mg，0.03067mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得15mg化合物8，收率88％。
化合物8结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝15.0Hz,2H),7.59–7.48(m,3H),7.31–7.13(m,8H),7.13–7.06(m,3H),7.03(d,J＝15.0Hz,3H),6.81(d,J＝30.2Hz,1H),2.67–2.57(m,2H),2.56–2.45(m,2H).
13C NMR(101MHz,CDCl3)δ176.11,168.48,146.93,145.50,143.45,137.17,134.27,132.81,132.03,131.41,129.62,129.37,129.27,128.06,127.96,127.93,127.62,124.67,124.16,124.08,123.50,123.46,122.99,116.02,76.95,35.25,30.23.
HRMS(ESI)Calcd for:C35H26N3O2S+([M+H]+):552.6715.Found:552.6765.
Figure BDA0001677435080000071
实施例6：化合物10的制备
取化合物2(445mg，1mmol)、化合物9(271mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得440mg化合物10。收率：63％。
化合物10结构测定数据如下：
1H NMR(400MHz,CDCl3)δ8.77–8.69(m,1H),7.79–7.71(m,1H),7.63(s,1H),7.59–7.50(m,2H),7.43–7.30(m,4H),7.20–7.06(m,9H),7.03(d,J＝8.6Hz,2H),4.26–4.16(m,2H),2.96(t,J＝7.8Hz,2H),2.65(t,J＝7.8Hz,2H),1.06–0.98(m,2H),0.07(s,9H).
13C NMR(101MHz,CDCl3)δ173.07,158.80,150.09,149.92,146.71,144.82,138.14,136.83,133.80,131.63,129.56,129.50,129.41,128.94,128.09,127.65,127.10,125.75,125.45,124.48,124.22,122.73,121.33,117.03,115.82,71.53,62.78,36.02,30.41,17.33,-1.42.
HRMS(ESI)Calcd for:C40H38N3O2SeSi+([M+H]+):699.8075.Found:699.8099.
实施例7：化合物11的制备
取化合物10(20mg，0.02857mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得15mg化合物11，收率87％。
化合物11结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.31–7.20(m,6H),7.19–7.08(m,5H),7.08–6.90(m,4H),6.86–6.73(m,3H),2.68–2.57(m,2H),2.56–2.44(m,2H).
13C NMR(101MHz,CDCl3)δ176.11,167.44,146.93,145.50,143.45,137.16,135.46,132.81,132.03,131.44,131.37,129.67,129.37,129.27,128.36,128.24,126.13,124.67,123.50,123.46,122.99,120.45,116.02,115.42,68.22,35.25,30.23.
HRMS(ESI)Calcd for:C35H26N3O2Se+([M+H]+):599.5715.Found:599.5786.
Figure BDA0001677435080000081
实施例8：化合物13的制备
取化合物12(416mg，1mmol)、化合物3(208mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得357mg化合物13。产率59％。
化合物13结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.50(s,1H),7.44–7.18(m,5H),7.13(dd,J＝21.0,5.9Hz,5H),7.04(dt,J＝14.7,5.0Hz,4H),6.92–6.73(m,3H),5.66(s,1H),3.03(td,J＝15.4,1.4Hz,2H),2.62(td,J＝15.4,1.4Hz,2H),1.42(s,9H).
13C NMR(101MHz,CDCl3)δ162.72,158.57,157.25,150.17,146.93,145.50,143.87,136.93,132.81,132.03,130.66,129.84,129.27,128.41,125.14,124.67,124.29,123.50,122.99,121.87,121.32,119.34,118.76,116.02,110.50,80.89,80.10,43.43,35.82,28.33.
HRMS(ESI)Calcd for:C39H35N4O3 +([M+H]+):607.7335.Found:607.7356.
实施例9：化合物14的制备
取化合物13(20mg，0.03296mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得16mg化合物14，收率95％。
化合物14结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.44–7.18(m,5H),7.13(dd,J＝21.0,5.9Hz,5H),7.04(dt,J＝14.7,5.0Hz,4H),6.92–6.74(m,3H),5.66(s,1H),3.09–2.89(m,2H),2.81–2.62(m,2H),1.60(s,2H).
13C NMR(101MHz,CDCl3)δ162.72,157.25,150.17,146.93,145.50,143.67,137.04,132.81,132.03,130.66,129.89,129.27,128.41,125.14,124.67,124.29,123.50,122.99,121.77,121.32,119.34,118.76,116.02,110.50,80.10,42.41,37.78.
HRMS(ESI)Calcd for:C34H27N4O+([M+H]+):507.6165.Found:507.6178.
Figure BDA0001677435080000091
实施例10：化合物15的制备
取化合物12(416mg，1mmol)、化合物6(224mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得384mg化合物15。收率：60％。
化合物15结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.60–7.47(m,3H),7.32–7.22(m,3H),7.22–7.09(m,6H),7.05(t,J＝5.1Hz,2H),7.00(d,J＝4.7Hz,1H),6.83(d,J＝4.0Hz,2H),6.58(s,1H),3.03(td,J＝15.4,1.4Hz,2H),2.62(td,J＝15.4,1.3Hz,2H),1.42(s,9H).
13C NMR(101MHz,CDCl3)δ168.48,158.57,146.93,145.50,143.87,136.93,134.27,132.81,132.03,131.41,129.84,129.62,129.27,128.06,127.96,127.93,127.62,124.67,124.16,124.08,123.50,122.99,121.87,116.02,80.89,76.95,43.43,35.82,28.33.
HRMS(ESI)Calcdfor:C39H35N4O2S+([M+H]+):623.7945.Found:623.7965.
实施例11：化合物16的制备
取化合物15(20mg，0.03211mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得16mg化合物16，收率95％。
化合物16结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.54(dd,J＝5.6,3.1Hz,2H),7.24(ddd,J＝17.0,7.5,3.3Hz,5H),7.13(dd,J＝21.0,5.9Hz,4H),7.02(dt,J＝19.4,9.9Hz,4H),6.83(d,J＝4.0Hz,2H),6.58(s,1H),3.08–2.92(m,2H),2.80–2.63(m,2H),1.60(s,2H).
13C NMR(101MHz,CDCl3)δ168.48,146.93,145.50,143.67,137.04,134.27,132.81,132.03,131.41,129.89,129.62,129.27,128.06,127.96,127.93,127.62,124.67,124.16,124.08,123.50,122.99,121.77,116.02,76.95,42.41,37.78.
HRMS(ESI)Calcd for:C34H27N4S+([M+H]+):523.6775.Found:523.6787.
Figure BDA0001677435080000111
实施例12：化合物17的制备
取化合物12(416mg，1mmol)、化合物9(271mg，1mmol)加入100mL圆底烧瓶中，在氩气保护下加入甲苯45mL溶解，加入哌啶0.5mL、醋酸0.5mL，氩气保护下在115℃油浴中加热回流反应12小时。反应结束后，冷却至室温，旋蒸除去甲苯，直接过硅胶柱分离纯化(PE:EA＝10:1)得375mg化合物17。收率：56％。
化合物7结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.50(s,1H),7.32–7.16(m,8H),7.13(d,J＝15.1Hz,2H),7.08(d,J＝14.8Hz,2H),7.05–6.95(m,3H),6.85–6.76(m,3H),3.03(d,J＝1.0Hz,1H),2.62(d,J＝1.0Hz,1H),1.42(s,9H).
13C NMR(101MHz,CDCl3)δ167.44,158.57,146.93,145.50,143.87,136.93,135.46,132.81,132.03,131.44,131.37,129.84,129.67,129.27,128.35,128.24,126.13,124.67,123.50,122.99,121.87,120.45,116.02,115.42,80.89,68.22,43.43,35.82,28.33.
HRMS(ESI)Calcd for:C39H35N4O2Se+([M+H]+):670.6945.Found:670.6967.
实施例13：化合物18的制备
取化合物17(20mg，0.02986mmol)加入5mL圆底烧瓶中，在氩气保护下加入二氯甲烷1mL，置于冰浴中，滴加三氟乙酸0.5mL。反应液在25℃机械搅拌反应6小时。反应结束后直接旋蒸去除溶剂，过硅胶柱分离纯化(DCM:MeOH＝20:1)、得13mg化合物18，收率76％。
化合物18结构测定数据如下：
1H NMR(400MHz,CDCl3)δ7.77(d,J＝14.9Hz,2H),7.30–7.13(m,9H),7.10(d,J＝5.7Hz,2H),7.02(dt,J＝19.4,9.9Hz,4H),6.86–6.65(m,3H),3.17–2.87(m,2H),2.82–2.47(m,2H),1.60(s,2H).
13C NMR(101MHz,CDCl3)δ167.44,146.93,145.50,143.67,137.04,135.46,132.81,132.03,131.44,131.37,129.89,129.67,129.27,128.35,128.24,126.13,124.67,123.50,122.99,121.77,120.45,116.02,115.42,68.22,42.41,37.78.
HRMS(ESI)Calcd for:C34H27N4Se+([M+H]+):570.5775.Found:570.5779.
实施例14：化合物1a的制备及其肿瘤成像效果
Figure BDA0001677435080000121
取化合物8(1.3mg，0.0024mmol)加入5mL圆底烧瓶中，在氩气保护下加入无水DMF1mL，搅拌使溶解，随后加入HATU(1.14mg，0.003mmol)和DIPEA(5μL)，搅拌十分钟后，加入化合物6(0.766mg，0.003mmol)，反应液在25℃搅拌反应3小时。将多肽CREKA(1.817mg，0.003mmol)在300μL PBS中，用TCEP(0.86mg，0.003mmol)预处理10分钟后加入到反应体系中，室温反应6小时。反应结束后加乙醚沉淀，收集固体，固体复溶于去离子水-乙腈(v/v，7:3)中，通过半制备型高效液相色谱纯化，冻干得产品。
化合物1a结构测定数据如下：
MALDI-TOF-MSCalcdfor:C64H74N14O11S2:1279.5030,found:1280.5671.
通过尾静脉注射1a 50μg的PBS溶液200μL进入右前肢接种肿瘤细胞的荷瘤小鼠体内，近红外成像仪拍摄小鼠全身成像图，参见图3，肿瘤部位能够和其他组织明显区别。表明，荧光探针1a对肿瘤的主动靶向性较好。本发明所述材料在特异性诊断肿瘤方面具有较好的应用前景。

Claims (6)

1.含4-二氰基甲基苯并吡喃单元的近红外染料，其特征在于：其结构式如下所示：
Figure FDA0003576605330000011
2.根据权利要求1所述的近红外染料，其特征在于：其荧光发射波长为680～800nm。
3.一种用于生物体内成像的近红外荧光探针，其特征在于：在权利要求1所述结构式所示的近红外染料可修饰位点上修饰聚乙二醇、多肽、蛋白、核酸适配体或叶酸。
4.权利要求3所述的近红外荧光探针在制备癌症诊断试剂上的应用。
5.根据权利要求4所述的应用，其特征在于：所述癌症为肺癌、脑胶质瘤、乳腺癌、前列腺癌、黑色素瘤、结肠癌、胃癌、食道癌、宫颈癌或卵巢癌。
6.权利要求1或2所述的近红外染料在制备生物体内成像试剂中的应用。
CN201810534253.5A 2018-05-29 2018-05-29 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用 Active CN108892654B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810534253.5A CN108892654B (zh) 2018-05-29 2018-05-29 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810534253.5A CN108892654B (zh) 2018-05-29 2018-05-29 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN108892654A CN108892654A (zh) 2018-11-27
CN108892654B true CN108892654B (zh) 2022-06-14

Family

ID=64343469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810534253.5A Active CN108892654B (zh) 2018-05-29 2018-05-29 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN108892654B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456304A (zh) * 2018-12-05 2019-03-12 武汉大学 易修饰近红外二区有机小分子染料及其合成方法和应用
CN109970780B (zh) * 2019-03-12 2021-06-18 武汉大学深圳研究院 近红外荧光化合物及制备方法、近红外荧光成像探针及其应用
CN113552099B (zh) * 2020-04-24 2024-04-16 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种荧光诊断试剂盒及其应用
CN111689950B (zh) * 2020-07-24 2022-11-11 山东大学 一种基于二苯胺基的有机双杂环近红外荧光探针及其制备方法与应用
CN112142721B (zh) * 2020-09-04 2022-02-11 武汉大学深圳研究院 一种可靶向线粒体的近红外二区噻喃盐荧光化合物及其制备方法与应用
CN113337275B (zh) * 2021-04-25 2022-11-01 江苏新视界先进功能纤维创新中心有限公司 一种抗菌aie材料及其制备方法
CN114478581B (zh) * 2022-01-05 2023-04-07 西藏大学 光治疗的nir-ii小分子、化合物、配合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3539628B2 (ja) * 1999-09-17 2004-07-07 富士写真フイルム株式会社 発光素子材料、それを使用した発光素子およびアミン化合物
JP3743229B2 (ja) * 1999-10-22 2006-02-08 凸版印刷株式会社 有機薄膜発光素子及び蛍光体
CN102041556A (zh) * 2009-10-20 2011-05-04 中国科学院理化技术研究所 溶液法制备单晶一维或准一维有机纳米材料的方法
CN102702096B (zh) * 2012-06-15 2013-12-25 华东理工大学 具有聚集诱导发光性能的喹啉腈衍生物
JP5907289B1 (ja) * 2015-02-06 2016-04-26 東洋インキＳｃホールディングス株式会社 有機エレクトロルミネッセンス素子用材料およびその用途

Also Published As

Publication number Publication date
CN108892654A (zh) 2018-11-27

Similar Documents

Publication Publication Date Title
CN108892654B (zh) 含4-二氰基甲基苯并吡喃单元的近红外荧光染料及其制备方法和应用
CN106977529B (zh) 一类可修饰的近红外二区荧光成像探针及其制备方法和用途
CN109336909B (zh) 具有聚集诱导发光性质的近红外二区荧光化合物及制备方法、纳米粒胶束及其应用
CN101440282B (zh) 近红外荧光分子探针及其合成方法和用途
CN109641921B (zh) 分子荧光团及其制备方法和用于短波红外成像的用途
CN105073761A (zh) 用于体外和体内成像和检测的取代的硅杂蒽阳离子红至近红外荧光染料
CN109010826A (zh) 一种基于吲哚方酸菁染料的靶向材料及其制备方法和荧光纳米粒子及其制备方法
Li et al. Hypoxia-activated probe for NIR fluorescence and photoacoustic dual-mode tumor imaging
CN114933633B (zh) 一种特异性识别fgfr4的天然肽探针及其应用
CN108948142A (zh) 一种靶向肿瘤细胞及新生血管的荧光探针及其制备方法
CN114249717A (zh) 特异性靶向肿瘤的近红外荧光探针及其合成方法和应用
CN109369633B (zh) 一种可靶向线粒体的近红外二区荧光化合物及其制备方法与应用
CN111925311A (zh) 肿瘤造影化合物、其制备方法及在肿瘤诊断成像中的应用
CN109970780B (zh) 近红外荧光化合物及制备方法、近红外荧光成像探针及其应用
CN112209990B (zh) 康普瑞汀类衍生物及其抗体药物偶联物
CN114716470B (zh) 不对称的供体-受体型近红外二区探针分子及其制备方法和应用
Mhlongo et al. Microwave-assisted synthesis of meso-carboxyalkyl-BODIPYs and an application to fluorescence imaging
CN107522773B (zh) 一种五肽改性罗丹明b化合物及其制备方法和应用
CN112480212A (zh) 靶向肝细胞生长因子的高亲和肽及其应用
CN114805397A (zh) 可在体内长时间循环的有机荧光小分子化合物及其制备方法和应用
JP2023525601A (ja) 腫瘍組織を標識するための新規蛍光化合物
KR101809828B1 (ko) 타이로신 인산화 효소를 감지하는 진보된 감지계 및 이의 용도
KR102034113B1 (ko) 종양특이성을 증가시킨 신장배출형 형광 조영제 및 이를 이용한 영상화 방법
CN113004254B (zh) 以吲哚氰绿衍生物为载体的配体及其制备方法与应用
CN114632079B (zh) 一种基于青蒿素的铁池靶向分子影像探针制备及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant